# Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

> **NCT02934828** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 230 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant Chemotherapy
- **DRUG:** postoperative chemotherapy

## Key facts

- **NCT ID:** NCT02934828
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2016-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02934828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02934828, "Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02934828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*